65至74岁成人序贯接种增强型流感疫苗的血清学应答:开放标签随机试验
160名65至74岁成人按1:1:1随机接种标准剂量、高剂量或MF59佐剂三价灭活流感疫苗,第二季高剂量组和佐剂组续用原疫苗,标准剂量组再随机分至高剂量或佐剂组。分析152人,第二季高剂量→高剂量与佐剂→佐剂组GMT及滴度≥40比例无差异,但均高于标准剂量→佐剂组对A/H1N1的滴度≥40比例(86%-89%对60%)。结论:序贯接种增强型疫苗未降低免疫原性。
要点
- 高剂量→高剂量与佐剂→佐剂组第二季GMT和滴度≥40比例无差异。
- 对A/H1N1,高剂量→高剂量和佐剂→佐剂组滴度≥40比例86%-89%,高于标准剂量→佐剂组的60%。
- 所有组对细胞培养A/H3N2的血清学应答均不理想,第二季MFR为1.5-2.2。
核心结论
- 序贯接种增强型疫苗未降低65至74岁成人的免疫原性,但对细胞培养A/H3N2的血清学应答在所有疫苗中均不理想。
研究设计与样本
- 探索性开放标签随机试验,纳入160名65至74岁成人,2016/17年按1:1:1随机接种三价灭活标准剂量、高剂量或MF59佐剂疫苗。
- 2017/18年高剂量组和佐剂组续用原疫苗,标准剂量组再随机分至高剂量或佐剂组。
- 分析纳入152人:高剂量→高剂量55人,佐剂→佐剂58人,标准剂量→高剂量19人,标准剂量→佐剂20人。
主要发现
- 第二季接种后,高剂量→高剂量与佐剂→佐剂组间疫苗株GMT和滴度≥40比例无差异。
- 对A/H1N1,高剂量→高剂量和佐剂→佐剂组滴度≥40比例86%-89%,高于标准剂量→佐剂组的60%。
- 对A/H3N2,高剂量→高剂量和佐剂→佐剂组滴度≥40比例83%-87%,高于标准剂量→佐剂和标准剂量→高剂量组的40%-53%。
- 佐剂→佐剂组GMT高于标准剂量→佐剂组:A/H1N1 p=.01,A/H3N2 p=.002。
- 第二季MFR在所有组对A/H3N2为1.5-2.2、对B/Victoria为1.7-2.3;高剂量→高剂量和佐剂→佐剂组第二季MFR为1.6-3.7,低于第一季的2.6-6.2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effects of sequential vaccination with enhanced influenza vaccines are poorly understood. We conducted an exploratory open-label study to assess serologic response to sequential vaccination in older adults. METHODS: 160 adults aged 65 through 74 years were randomized (1:1:1) to receive trivalent inactivated standard dose (SD), high-dose (HD), or MF59-adjuvanted (AD) vaccine in 2016/17. In 2017/18, HD and AD recipients received the same vaccine; SD recipients were re-randomized to HD or AD. Hemagglutination inhibition assays were performed using turkey erythrocytes against A/California/7/2009(H1N1)-like and B/Brisbane/60/2008(B/Victoria)-like in both seasons, and A/Michigan/45/2015(H1N1)-like in season 2. Microneutralization assays were performed against cell-propagated A/Hong Kong/4801/2014(H3N2)-like using MDCK-SIAT1 cells. Postvaccination geometric mean titer (GMT), percent with titer ≥ 40, and mean fold rise (MFR, ratio of postvaccination versus prevaccination titer) in season 2 were compared across groups, and ratio of MFR in season 2 versus season 1 was assessed for each strain. RESULTS: Analysis included 152 participants (55 HD → HD, 58 AD → AD, 19 SD → HD, and 20 SD → AD). Season 2 postvaccination GMTs and percent with titer ≥ 40 did not differ between HD → HD and AD → AD recipients for vaccine strains examined. However, a higher percent of HD → HD and AD → AD recipients had postvaccination titer ≥ 40 than SD → AD recipients for A/H1N1 (86%-89% versus 60%) and SD → AD and SD → HD recipients for A/H3N2 (83%-87% versus 40%-53%). GMTs were higher in AD → AD versus SD → AD recipients for A/H1N1 (p = .01) and A/H3N2 (p = .002). MFRs in season 2 were low in all groups for A/H3N2 (1.5-2.2) and B/Victoria (1.7-2.3). MFR was lower in season 2 versus 1 for HD → HD and AD → AD recipients for all vaccine strains (1.6-3.7 versus 2.6-6.2). CONCLUSIONS: Sequential vaccination with enhanced vaccines did not reduce immunogenicity in adults aged 65 through 74 years. Serologic response to cell-propagated A/H3N2 was suboptimal for all vaccines. ClinicalTrials.gov identifier. NCT02872311.
引用
- McLean HQ, Levine MZ, King JP, et al. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65-74 years. Vaccine. 2021. PMID: 34774360. doi:10.1016/j.vaccine.2021.10.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。